Acquired C797S mutation upon treatment with a T790M-specific third-generation EGFR inhibitor (HM61713) in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages e45-e47

  Song, Haa Na ^a,b   Jung, Ki Sun ^a   Yoo, Kwai Han ^a   Cho, Jinhyun ^a   Lee, Ji Yun ^a   Lim, Sung Hee ^a   Kim, Hae Su ^a   Sun, Jong Mu ^a   Lee, Se Hoon ^a   Ahn, Jin Seok ^a   Park, Keunchil ^a   Choi, Yoon La ^a   Park, Woongyang ^a,c   Ahn, Myung Ju ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Gyeongsang National University School of Medicine   (South Korea)

^c Samsung Advanced Institute of Technology (SAIT)   (South Korea)

Author keywords

C797S mutation; EGFR; HM61713; T790M mutation

Indexed keywords

AFATINIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HM 61713; NIMOTUZUMAB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BRAIN METASTASIS; CANCER RESISTANCE; CASE REPORT; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; ADENOCARCINOMA; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84962799612     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2015.12.093     Document Type: Article

References (5)

1. Park K, Lee JS, Lee KH, et al. Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI) [ASCO abstract 8084] J Clin Oncol. 2015;33(suppl).
2. Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689-1699.
3. Yu HA, Tian SK, Drilon AE, et al. Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain. JAMA Oncol. 2015;1:982-984.
4. Planchard D, Loriot Y, Andre F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. Ann Oncol. 2015;26:2073-2078.
5. Eberlein CA, Stetson D, Markovets AA, et al. Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res. 2015;75:2489-2500.